Zenas BioPharma, Inc. (ZBIO)

Every figure this model derived for ZBIO, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 2,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 643,126,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 653,794,000 AssetsCurrent 2026-06-30
current liabilities 65,818,000 LiabilitiesCurrent 2026-06-30
equity 247,097,000 StockholdersEquity 2026-06-30
interest expense 2,088,000 InterestExpenseDebt 2026-06-30
ocf -225,972,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 10,000,000 Revenues 2025-12-31
sbc 32,730,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ZBIO on one particular measure came for.

RatioValue
current ratio9.93
current ratio reported9.93
dilution pct239.17
fcf margin-2259.74
interest cover-227.76
revenue growth100.0
revenue growth per share-41.03
rule of 40-4655.73
sbc pct revenue327.3

What to be careful about

What this model itself distrusts about ZBIO's figures. Written by the derivation as it ran, not added afterwards.